NASDAQ:IMGN ImmunoGen (IMGN) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free IMGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$31.23▼$31.2350-Day Range$31.23▼$31.2352-Week Range$3.61▼$31.25Volume40 shsAverage Volume8.78 million shsMarket Capitalization$8.32 billionP/E RatioN/ADividend YieldN/APrice Target$25.77 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Get ImmunoGen alerts: Email Address ImmunoGen MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside17.5% Downside$25.77 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth362.50%From $0.08 to $0.37 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector853rd out of 918 stocksBiotechnology Industry34th out of 43 stocks 1.1 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunoGen has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IMGN. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 69.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.78. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for ImmunoGen this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for IMGN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.07% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow by 362.50% in the coming year, from $0.08 to $0.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 43.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceNew crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. About ImmunoGen Stock (NASDAQ:IMGN)ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Read More Ad InvestorPlaceNew crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. IMGN Stock News HeadlinesApril 18, 2024 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Coverage Initiated by Analysts at StockNews.comApril 17, 2024 | americanbankingnews.comImmunoGen, Inc. (NASDAQ:IMGN) Receives Consensus Recommendation of "Hold" from AnalystsApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 10, 2024 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Coverage Initiated at StockNews.comMarch 22, 2024 | marketwatch.comAbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen DealFebruary 21, 2024 | msn.comAbbVie plans to offer senior notes to fund Immunogen, Cerevel dealsFebruary 19, 2024 | ca.finance.yahoo.comCERE Aug 2024 30.000 callFebruary 12, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on ImmunoGen (IMGN)April 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.February 12, 2024 | msn.comAbbVie revises Q1 earnings outlook as ImmunoGen deal closesFebruary 9, 2024 | finance.yahoo.comIs ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?February 9, 2024 | seekingalpha.comFinal Countdown: AbbVie's Imminent Closure With ImmunoGen And What It MeansFebruary 9, 2024 | msn.comImmunoGen Set to Merge with AbbVie, Awaiting Final ApprovalFebruary 9, 2024 | finance.yahoo.comImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?February 2, 2024 | finance.yahoo.comImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 2, 2024 | finance.yahoo.comImmunoGen, Inc. (IMGN) Interactive Stock Chart - Yahoo FinanceJanuary 9, 2024 | finance.yahoo.comHow ImmunoGen (IMGN) Stock Stands Out in a Strong IndustryJanuary 4, 2024 | nasdaq.comIMGN Quantitative Stock AnalysisJanuary 4, 2024 | msn.comAll You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong BuyDecember 27, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLYDecember 22, 2023 | finance.yahoo.comAre Investors Undervaluing ImmunoGen, Inc. (NASDAQ:IMGN) By 38%?December 19, 2023 | morningstar.comImmunogen Inc IMGNDecember 16, 2023 | msn.comImmunogen (IMGN) Price Target Increased by 35.04% to 31.68December 7, 2023 | reuters.comAbbvie to focus on smaller deals after Cerevel and ImmunoGen buyoutDecember 7, 2023 | finance.yahoo.comAbbVie acquiring Cerevel Therapeutics in $8.7B dealDecember 5, 2023 | msn.comImmunoGen bags priority review for full approval of ovarian cancer drugDecember 5, 2023 | markets.businessinsider.comImmunoGen Receives FDA's Priority Review For ELAHERE In Platinum-Resistant Ovarian CancerSee More Headlines Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2023Today4/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Price Target and Rating Average Stock Price Target$25.77 High Stock Price Target$31.26 Low Stock Price Target$16.00 Potential Upside/Downside-17.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio390.38 P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$287.61 million Price / Sales28.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book43.99Miscellaneous Outstanding Shares266,264,000Free Float252,764,000Market Cap$8.32 billion OptionableOptionable Beta1.18 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Mark Joseph Enyedy (Age 60)President, CEO & Director Comp: $1.28MDr. Michael J. Vasconcelles M.D. (Age 61)Ph.D., Chief Medical Officer Comp: $304.62kMs. Lauren A. White M.B.A. (Age 45)Senior VP & Chief Financial Officer Anabel ChanHead of Investor RelationsMr. Daniel S. Char J.D. (Age 62)Senior VP, Chief Legal Officer & Secretary Ms. Courtney O'KonekSenior Director of Corporate Communications & Investor RelationsMs. Audrey BerganSenior VP & Chief HR OfficerDr. Theresa G. Wingrove (Age 66)Senior Vice President of Regulatory Affairs & Quality Comp: $548.21kMs. Isabel KalofonosSenior VP & Chief Commercial OfficerMore ExecutivesKey CompetitorsRoivant SciencesNASDAQ:ROIVRayzeBioNASDAQ:RYZBCrinetics PharmaceuticalsNASDAQ:CRNXBio-Rad LaboratoriesNYSE:BIOAscendis Pharma A/SNASDAQ:ASNDView All CompetitorsInsiders & InstitutionsKapitalo Investimentos LtdaBought 31,437 shares on 3/29/2024Ownership: 0.012%Leo Wealth LLCBought 25,016 shares on 3/14/2024Ownership: 0.009%Vanguard Group Inc.Bought 984,795 shares on 3/11/2024Ownership: 9.565%Wellington Management Group LLPSold 11,304,584 shares on 3/5/2024Ownership: 0.734%Twin Focus Capital Partners LLCSold 32,000 shares on 3/5/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions IMGN Stock Analysis - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price target for 2024? 12 analysts have issued twelve-month price targets for ImmunoGen's shares. Their IMGN share price targets range from $16.00 to $31.26. On average, they expect the company's stock price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 17.5%. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.14. The biotechnology company earned $83.20 million during the quarter, compared to the consensus estimate of $49.15 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%. The firm's quarterly revenue was up 485.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. What ETFs hold ImmunoGen's stock? ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Principal Healthcare Innovators ETF (BTEC), Invesco DWA SmallCap Momentum ETF (DWAS), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB). What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More This page (NASDAQ:IMGN) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.